Trials / Completed
CompletedNCT00035178
Pharmacokinetics/Pharmacodynamics of Argatroban Injection in End-Stage Renal Disease Patients Undergoing Hemodialysis
Pharmacokinetics and Pharmacodynamics of Argatroban Injection in End-Stage Renal Disease (ESRD) Patients Undergoing Hemodialysis
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 12 (planned)
- Sponsor
- Texas Biotechnology Corporation · Industry
- Sex
- All
- Age
- 21 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The primary goals of this investigation are to provide guidance on how to dose Argatroban in patients undergoing hemodialysis and to assess the safety and tolerability of Argatroban in hemodialysis patients. The secondary goal of the study will be to assess the adequacy of anticoagulation during hemodialysis.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Argatroban |
Timeline
- Start date
- 2002-05-01
- Completion
- 2002-11-01
- First posted
- 2002-05-03
- Last updated
- 2005-06-24
Locations
2 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00035178. Inclusion in this directory is not an endorsement.